The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—in particular, disease-modifying therapies (DMTs) that can slow the course of the disease. In response, drug developers—from big pharma to small biotech—continue to invest heavily in disease-modifying approaches due to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. While, many uncertainties remain about the approval prospects for aducanumab, and the fate of anti-amyloid MAbs from Biogen / Eisai (BAN2401) and Roche (gantenerumab) in their ongoing Phase III trials, key opinion leaders (KOLs) are cautiously optimistic about the anti-tau therapies (approximately 15) in early- to mid-phase trials, and hope remains for the late-phase therapies from Lundbeck / Otsuka, Avanir / Otsuka, and Acadia that are in development for the treatment of AD agitation and psychosis, respectively. Ultimately, however, the launch of any of these is far from guaranteed.
- What are the drivers and constraints in the AD market?
- How large is the treatable AD population? What commercial uptake can be expected from Rexulti, AVP-786, and Nuplazid should they launch?
- What will be the impact of DMTs—should any of them launch—on diagnosis, drug treatment, and revenue, and which populations will be most affected?
- What are the key learning points from the recent failure of late-phase anti-amyloid therapies, and what are experts’ opinions of the launch prospects for agents still in development, such as Biogen / Eisai’s BAN2401?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.